- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04986085
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor (NUTRIGETNE)
Nutritional Status of Patients With Gastroenteropancreatic Neuroendocrine Tumors in Spain: NUTRIGETNE
It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments. In patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET), due to their heterogeneity and longer survival, it is expected that the prevalence of malnutrition is probably underdiagnosed, as well as the existence of a negative impact on different parameters (quality of life, survival). So far, the studies carried out on nutrition and NET are very scarce and none has been carried out so far in Spain.
Before being able to carry out nutritional intervention studies on these patients, it is necessary to know the reality of the nutritional status of patients with NETs in Spain. The main motivation for the NUTRIGETNE study is to evaluate the epidemiological status of nutrition in NETs in the spanish population. In addition to know the epidemiological picture, it is intended to study the nutritional status from different points of view: analytical, clinical, anthropometric, etc. Besides, the study of nutritional status will allow us to closely monitor the patients who have a higher risk of malnutrition and to propose early interventions for those, as well as the impact of their nutritional status on different parameters: survival, hospitalization, quality of life or responses to the treatments.
NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status of patients with GEP NET in Spain will be evaluated.
Study Overview
Status
Conditions
Detailed Description
NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status of patients with GEP NET in Spain will be evaluated. It is planned to include 400 GEP NET patients. Patients will be included consecutively when visiting the corresponding health centers for outpatient visits or hospitalization.
The study comprises 3 stages with a total duration of 10 to 40 days for the participation of each subject in the study:
Screening visit, First day (day 0): The initial screening will take place on the first day the patient visits the hospital. The inclusion and exclusion criteria will be reviewed to assess the eligibility of the patient. The implications of the study will be explained to the patient and the informed consent will be signed.
Visit for assessment of nutritional status (days 0-10): taking a medical history, complete physical examination including anthropometry, bioelectrical impedance (BIA) and dynamometry, as well as laboratory analysis. The evaluation of the nutritional status will be carried out by a registered nutritionist, specialized nurse or specialist doctor (variable depending on the characteristics of the center).
Data collection (day 10-40): collection of analytical, anthropometric, BIA, dynamometry and clinical results and introduction into the electronic case report form (eCRF).
After the end of recruitment and database lock, all data will be subsequently analyzed and presented when applicable through study reports and scientific communications.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall D´Hebron
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Córdoba, Spain, 14004
- Recruiting
- Hospital Universitario Reina Sofía
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Gerona, Spain, 17007
- Recruiting
- Hospital Universitario Dr. Josep Trueta
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Gijón, Spain, 33394
- Recruiting
- Hospital Universitario de Cabueñes
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramón y Cajal
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain, 28006
- Recruiting
- Hospital Universitario La Princesa
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Clinico San Carlos
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Oviedo, Spain, 33011
- Recruiting
- Hospital Universitario Central de Asturias
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Santander, Spain, 39008
- Recruiting
- Hospital Universitario Marques de Valdecilla
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Santiago De Compostela, Spain, 15706
- Recruiting
- Hospital Clinico Universitario de Santiago
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Valencia, Spain, 40026
- Recruiting
- Hospital Universitari i Poliècnic la Fe
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Principal Investigator:
- Principal investigator selected by the sponsor, M.D. Ph.D.
-
Valencia, Spain, 46009
- Recruiting
- Institut Valencià d'Oncologia (IVO)
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
Zaragoza, Spain, 50009
- Recruiting
- Hospital Universitario Miguel Servet
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Recruiting
- Hospital Universitario Virgen de la Arrixaca
-
Contact:
- A responsible person designated by the sponsor
- Email: investigacion@mfar.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with a gastroenteropancreatic neuroendocrine tumor by histopathological study.
- Legally capable patients ≥ 18 and ≤ 80 years of age.
- Patients who have signed the informed consent for this study as specified in section 10.3.
- Patients in active treatment: active treatment is considered to be those patients in an advanced stage and in any type of medical treatment (somatostatin analogues, molecular therapies, chemotherapy, radionuclides...), or locoregional therapies.
Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.
Exclusion Criteria:
- Patients <18 or > 80 years of age.
- Female patients that are currently pregnant.
- Patients with a gastroenteropancreatic neuroendocrine tumor lacking an histopathological diagnosis.
- Patients in palliative treatment or terminal stage.
- Patients who have not signed the informed consent or any situation or condition that compromises the giving of patient voluntary informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
GEP NET
GEP NET patients in Spain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of malnutrition in GEP NET
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Percentage of GEP NET patients suffering from malnutrition in Spain.
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Risk of malnutrition in GEP NET
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Percentage of GEP NET patients at risk of suffering from malnutrition in Spain.
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body mass index
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Body mass index (BMI) is defined as a a measure of body fat based on height and weight that applies to adult men and women
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Body fat
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Body fat mass calculated by bioimpedance
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Body muscle mass
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Body muscle mass calculated by bioimpedance
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Nutritional Risk Screening (NRS) rates
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Scale to evaluate the malnutrition in adult patients.
It is based in the assessment of BMI, weight loss in the last 3-6 months and acute disease effects.
The score ranges from 0 (low malnutrition risk to 6 (high malnutrition risk).
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Subjective Global Assessment (SGA) rates
Time Frame: Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Score to measure risk malnutrition in adult patients based on patient history and physical examination alone.
The score has 3 levels: A (low malnutrition risk) to C (high malnutrition risk)
|
Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)
|
Collaborators and Investigators
Investigators
- Principal Investigator: María Isabel del Olmo García, M.D. Ph.D., Hospital Universitario La Fe
- Principal Investigator: María Argente Pla, M.D. Ph.D., Hospital Universitario La Fe
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Intestinal Diseases
- Pancreatic Diseases
- Stomach Neoplasms
- Pancreatic Neoplasms
- Neuroendocrine Tumors
- Intestinal Neoplasms
Other Study ID Numbers
- GETNE-S2109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroenteropancreatic Neuroendocrine Tumor
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
University Hospital, AntwerpErasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research... and other collaboratorsRecruitingGastroenteropancreatic Neuroendocrine TumorNetherlands, Belgium
-
University of IowaPatient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaboratorsEnrolling by invitationNeuroendocrine Tumors | Neuroendocrine Carcinoma | Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedLung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorUnited States
-
RayzeBio, Inc.RecruitingNeuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NETUnited States, Canada, Belgium, Netherlands, Spain, France, Brazil
-
Wren Laboratories LLCActive, not recruitingNeuroendocrine Tumor | GastroenteropancreaticItaly
-
IpsenCompletedGastro-Enteropancreatic Neuroendocrine TumorUnited States, Austria, Denmark